Capricor says HOPE-3 extension data show Deramiocel slows Duchenne upper-limb decline by 76% in delayed-start group
Bitget2026/10/05 13:08Capricor Therapeutics disclosed new 24-month HOPE-3 open-label extension data on deramiocel in Duchenne muscular dystrophy. Results were presented at the 2026 World Muscle Society Congress; a patient-focused webinar is set for Oct. 7, 2026. Patients who switched from placebo to deramiocel showed a marked slowdown in upper-limb functional decline versus their prior year. Two-year data in both study groups indicated slower deterioration than expected from untreated disease progression. Data were added to deramiocel’s BLA; FDA action is due by the Nov. 22, 2026 PDUFA target date. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050900PRIMZONEFULLFEED9839308) on October 05, 2026, and is solely responsible for the information contained therein.
- Capricor Therapeutics disclosed new 24-month HOPE-3 open-label extension data on deramiocel in Duchenne muscular dystrophy.
- Results were presented at the 2026 World Muscle Society Congress; a patient-focused webinar is set for Oct. 7, 2026.
- Patients who switched from placebo to deramiocel showed a marked slowdown in upper-limb functional decline versus their prior year.
- Two-year data in both study groups indicated slower deterioration than expected from untreated disease progression.
- Data were added to deramiocel’s BLA; FDA action is due by the Nov. 22, 2026 PDUFA target date.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
About 700,000 BTC have flowed out of exchanges in the past year.
Korean retail investors shift to the US in Q3: Sold over 5.5 trillion won of Korean stocks, purchased more than 10 trillion won of US stocks
In the third quarter, Korean retail investors made net purchases of US stocks worth approximately 10.15 trillion won, marking a complete reversal from the previous pattern in the first half of the year, when they made net purchases of nearly 100 trillion won in KOSPI stocks. In September alone, the sell-off amount reached as high as 14.2 trillion won. Analysts attribute this shift to a combination of factors: a sharp decline in KOSPI at high levels, the continued strength of the US stock market driven by AI themes, and the appreciation of the Korean won reducing currency exchange costs.
Crypto prices
More
